The Parnassus Mid Cap Growth Fund returned -5.21% in Q3 2026, outperforming the Russell Midcap Growth Index's -5.84%. Strong returns from Health Care holdings were the main driver, while Information Technology and an underweight position in Energy detracted from performance. Year-to-date, the fund gained 5.80%, beating the index's 1.01%. The fund also reduced exposure to Consumer Discretionary and housing sectors during the quarter.
The Parnassus Mid Cap Growth Fund's Q3 2026 performance is provided here as market context. For readers following Health Care stocks, 126 of 150 priced US Health-sector stocks on Pluang rose today. Notable movers include Merck & Co., Inc. at USD 148.52 with a 1-day change of +5.24%, Moderna, Inc. at USD 224.12 with +4.65%, and Biogen Inc at USD 255.01 with +4.49%, as of Oct 29, 2026 20:51 WIB.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
